CoChat

Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus

Open access

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Sodium glucose co-transporter 2 (SGLT2) inhibitors exhibit diuretic activity, which is a possible mechanism underlying the cardiovascular benefit of these inhibitors. However, the osmotic diuresis-induced increase in urine volume, and the risk of dehydration have been of concern with SGLT2 inhibitor treatment. This study aimed to investigate the mechanism underlying SGLT2 inhibitor canagliflozin-induced diuresis in Japanese type 2 diabetes mellitus (T2DM) patients. METHODS: Thirteen T2DM patients received a daily oral dose of 100 mg canagliflozin before breakfast for 6 days. Blood and urine samples were collected at predetermined time points. The primary endpoint was evaluation of correlations between changes from baseline in urine volume and factors that are known to affect urine volume and between actual urine volume and these factors. RESULTS: Canagliflozin transiently increased urine volume and urinary sodium excretion on Day 1 with a return to baseline levels thereafter. Canagliflozin administration increased urinary glucose excretion, which was sustained during repeated-dose administration. Plasma atrial natriuretic peptide (ANP) and N-terminal pro-b-type natriuretic peptide (NT-proBNP) levels decreased, while plasma renin activity increased. On Day 1 of treatment, changes in sodium and potassium excretion were closely correlated with changes in urine output. A post hoc multiple regression analysis showed changes in sodium excretion and water intake as factors that affected urine volume change at Day 1. Furthermore, relative to that at baseline, canagliflozin decreased blood glucose throughout the day and increased plasma total GLP-1 after breakfast. CONCLUSION: Canagliflozin induced transient sodium excretion and did not induce water intake at Day 1; hence, natriuresis rather than glucose-induced osmotic diuresis may be a major factor involved in the canagliflozin-induced transient increase in urine output. In addition, canagliflozin decreased plasma ANP and NT-proBNP levels and increased plasma renin activity, which may be a compensatory mechanism for sodium retention, leading to subsequent urine output recovery. CLINICAL TRIAL REGISTRATION: UMIN000019462. FUNDING: Mitsubishi Tanabe Pharma Corporation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12325-016-0457-8

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Canagliflozin-induced changes in parameters that reflect urine volume. Changes in a 24-h urinary glucose excretion, b water intake, c 24-h urinary Na excretion, d 24-h urinary K excretion, e urine osmolality, f serum osmolality, g BUN/CRE, and h Ht. Numbers of patients: days 0, 1, 2, and 3, n = 13; days 4 and 5, n = 12. Data are expressed as mean ± SD
Fig. 1 Canagliflozin-induced changes in parameters that reflect urine volume. Changes in a 24-h urinary glucose excretion, b water intake, c 24-h urinary Na excretion, d 24-h urinary K excretion, e urine osmolality, f serum osmolality, g BUN/CRE, and h Ht. Numbers of patients: days 0, 1, 2, and 3, n = 13; days 4 and 5, n = 12. Data are expressed as mean ± SDCC BY-NC · PubMed Central
Fig. 2 Canagliflozin-induced changes in hormones levels and enzyme activity involved in homeostasis of body fluid and mineral balance. Changes in a NT-proBNP, b ANP, c renin activity, d aldosterone, and e vasopressin. Numbers of patients: day 0 and 1, n = 13; day 5, n = 12. Data are expressed as mean ± SD
Fig. 2 Canagliflozin-induced changes in hormones levels and enzyme activity involved in homeostasis of body fluid and mineral balance. Changes in a NT-proBNP, b ANP, c renin activity, d aldosterone, and e vasopressin. Numbers of patients: day 0 and 1, n = 13; day 5, n = 12. Data are expressed as mean ± SDCC BY-NC · PubMed Central
Fig. 3 Canagliflozin-induced changes in blood glucose and total GLP-1 after meals. Changes in a plasma glucose concentration over time, b postprandial blood glucose AUC after each meal, c plasma total GLP-1 after breakfast, and d total GLP-1 AUC0–2h after breakfast. Numbers of patients: day 0 and 1, n = 13; day 5, n = 12. Data are expressed as mean ± SD
Fig. 3 Canagliflozin-induced changes in blood glucose and total GLP-1 after meals. Changes in a plasma glucose concentration over time, b postprandial blood glucose AUC after each meal, c plasma total GLP-1 after breakfast, and d total GLP-1 AUC0–2h after breakfast. Numbers of patients: day 0 and 1, n = 13; day 5, n = 12. Data are expressed as mean ± SDCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 150

Metadata

Authors
Tanaka, H., Takano, K., Iijima, H., Kubo, H., Maruyama, N., Hashimoto, T., Arakawa, K., Togo, M., Inagaki, N., & Kaku, K.
Affiliations
  • Tanabe Pharma Corporation (Japan) (JP)
  • Kyoto University (JP)
  • Kawasaki Medical School (JP)
Corresponding author
Iijima, Hiroaki
Venue
Advances in Therapy
Published
2016-12-15
Volume
34
Issue
2
Pages
436-451
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
OpenAlex
W2562563466
Cited by
140
References
36
Citations by year
2026: 7 · 2025: 4 · 2024: 15 · 2023: 17 · 2022: 17 · 2021: 21 · 2020: 25 · 2019: 20 · 2018: 10 · 2017: 4
FWCI
11.38
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Advances in Therapy (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Mitsubishi Tanabe Pharma Corporation
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
canagliflozin, SGLT2 inhibitors, type 2 diabetes, urine output, diuresis, sodium excretion, osmotic diuresis, atrial natriuretic peptide, NT-proBNP, renin-angiotensin system, glucagon-like peptide-1, water intake, dehydration risk
MeSH terms
Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Adult, Blood Glucose, Dehydration, Diabetes Mellitus, Type 2, Female, Glycosuria, Humans, Hypoglycemic Agents, Japan, Male, Middle Aged, Peptide Fragments, Treatment Outcome, Natriuretic Peptide, Brain, Sodium-Glucose Transporter 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1007/s12325-016-0457-8
The paper
Tanaka, H., Takano, K., Iijima, H., Kubo, H., Maruyama, N., Hashimoto, T., Arakawa, K., Togo, M., Inagaki, N., & Kaku, K. (2017). Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus. Advances in Therapy. https://doi.org/10.1007/s12325-016-0457-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.